KM3900 was found to bind to CLDN4 on pancreatic and ovarian cancer cells but not normal cells, causing dose-dependent, antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in vitro, as well as in vivo tumor growth inhibition in mice models [198]. The gene discussed is CLDN4; the disease is ovarian cancer.